Current status and future perspectives on the medical treatment of neurocysticercosis

Pathogens and Global Health

Volumn 106, Issue 5, 2012, Pages 305-309

  Gonzales, Isidro ^a   Garcia, Hector H ^b  

^a INSTITUTO NACIONAL DE CIENCIAS NEUROLÓGICAS   (Peru)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

Cysticercosis; Neurocysticercosis; Peru; Taenia solium

Indexed keywords

ALBENDAZOLE; ANTICONVULSIVE AGENT; ANTIPARASITIC AGENT; CARBAMAZEPINE; OXFENDAZOLE; PHENYTOIN;

ARTICLE; BRAIN CYST; CYSTICERCOSIS; HUMAN; MORBIDITY; MORTALITY; NEUROCYSTICERCOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; SEIZURE;

ANTHELMINTICS; HUMANS; NEUROCYSTICERCOSIS; NEUROSURGICAL PROCEDURES;

EID: 84874880163     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/2047773212Y.0000000046     Document Type: Article

References (47)

1. Garcia HH, Del Brutto OH. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol. 2005;4:653-61.
2. Henneberg R. Die tierischen parasiten des zentralnervensystem. In: Lewandowsky M, editor. Handbuch der neurologie. Berlin: Verlag Von Julius Springer; 1912. p. 643-712.
3. McArthur WP. Cysticercosis as seen in the British army with special reference to the production of epilepsy. Trans R Soc Trop Med Hyg. 1934;27:343-63.
4. Dixon HB, Lipscomb, FM. Cysticercosis: an analysis and follow-up of 450 cases. London: Medical Research Council; 1961.
5. Mitchell WG, Crawford TO. Intraparenchymal cerebral cysticercosis in children: diagnosis and treatment. Pediatrics. 1988;82:76-82.
6. Del Brutto OH. Medical treatment of cysticercosis - effective. Arch Neurol. 1995;52:102-4.
7. Carpio A, Santillan F, Leon P, Flores C, Hauser WA. Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch Intern Med. 1995;155:1982-8.
8. Bickerstaff ER, Cloake PCP, Hughes B, Smith WT. The racemose form of cerebral cysticercosis. Brain. 1952;75:1-16.
9. Bickerstaff ER, Small JM, Woolf AL. Cysticercosis of the posterior fossa. Brain. 1956;79:622-34.
10. Estanol B, Corona T, Abad P. A prognostic classification of cerebral cysticercosis: therapeutic implications. J Neurol Neurosurg Psychiatry. 1986;49:1131-4.
11. Rajshekhar V, Chandy MJ. Solitary cysticercus granuloma: the disappearing lesion. Chennai: Orient Longman; 2000.
12. Chandy MJ, Rajshekhar V, Ghosh S, Prakash S, Joseph T, Abraham J, et al. Single small enhancing CT lesions in Indian patients with epilepsy: clinical, radiological and pathological considerations. J Neurol Neurosurg Psychiatry. 1991;54:702-5.
13. Singh G, Rajshekhar V, Murthy JM, Prabhakar S, Modi M, Khandelwal N, et al. A diagnostic and therapeutic scheme for a solitary cysticercus granuloma. Neurology. 2010;75:2236-45.
14. Mall RK, Agarwal A, Garg RK, Kar AM, Shukla R. Short course of prednisolone in Indian patients with solitary cysticercus granuloma and new-onset seizures. Epilepsia. 2003;44:1397-401.
15. Del Brutto OH, Santibanez R, Noboa CA, Aguirre R, Diaz E, Alarcon TA. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology. 1992;42:389-92.
16. Nash TE, Del Brutto OH, Butman JA, Corona T, Delgado-Escueta A, Duron RM, et al. Calcific neurocysticercosis and epileptogenesis. Neurology. 2004;62:1934-8.
17. Fleury A, Carrillo-Mezo R, Flisser A, Sciutto E, Corona T. Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease. Expert Rev Anti Infect Ther. 2010;9:123-33.
18. Proano JV, Madrazo I, Avelar F, Lopez-Felix B, Diaz G, Grijalva I. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med. 2001;345:879-85.
19. Nash TE, Garcia HH. Diagnosis and treatment of neurocysticercosis. Nat Rev Neurol. 2011;7:584-94.
20. Garcia HH, Gonzalez AE, Gilman RH. Cysticercosis of the central nervous system: how should it be managed? Curr Opin Infect Dis. 2011;24:423-7.
21. Carpio A. Neurocysticercosis: an update. Lancet Infect Dis. 2002;2:751-62.
22. Goel D, Mittal M, Bansal KK, Singhal A. Natural history of solitary cerebral cysticercosis cases after albendazole therapy: a longitudinal follow-up study from India. Acta Neurol Scand. 2010;121:204-8.
23. Nash TE, Mahanty S, Garcia HH. Corticosteroid use in neurocysticercosis. Expert Rev Neurother. 2011;11:1175-83.
24. Garcia HH, Pretell EJ, Gilman RH, Martinez SM, Moulton LH, Del Brutto OH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med. 2004;350:249-58.
25. Gonzalez AE, Falcon N, Gavidia C, Garcia HH, Tsang VC, Bernal T, et al. Time-response curve of oxfendazole in the treatment of swine cysticercosis. Am J Trop Med Hyg. 1998;59:832-6.
26. Del Brutto OH, Roos KL, Coffey CS, Garcia HH. Meta- analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med. 2006;145:43-51.
27. Abba K, Ramaratnam S, Ranganathan LN. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev. 2010;(1):CD000215.
28. Sinha S, Sharma BS. Intraventricular neurocysticercosis: a review of current status and management issues. Br J Neurosurg. 2012;26:305-9.
29. Rajshekhar V. Surgical management of neurocysticercosis. Int J Surg. 2010;8:100-4.
30. Zamora H, Castillo Y, Garcia HH, Pretell J, Rodriguez S, Dorny P, et al. Drop in antigen levels following successful treatment of subarachnoid neurocysticercosis. Am J Trop Med Hyg. 2005;73:S41.
31. Bobes RJ, Hernandez M, Marquez C, Fragoso G, Garcia E, Parkhouse RM, et al. Subarachnoidal and intraventricular human neurocysticercosis: application of an antigen detection assay for the diagnosis and follow-up. Trop Med Int Health. 2006;11:943-50.
32. Garcia HH, Dorny P, Castillo Y, Pretell EJ, Rodriguez S, Mija L, et al. Circulating antigen levels follow post-treatment evolution of subarachnoid neurocysticercosis. J Neuroparasitol. 2010;1:1-3.
33. Callacondo D, Garcia HH, Gonzales I, Escalante D, Nash TE. High frequency of spinal involvement in patients with basal subarachnoid neurocysticercosis. Neurology. 2012;78:1394-400.
34. Guo DM, Xie SP, Jia JP. Therapeutic efficacy of praziquantel, albendazole and a combination of the two drugs in cysticercosis. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2003;21:187-8.
35. Kaur S, Singhi P, Singhi S, Khandelwal N. Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J. 2009;28:403-6.
36. Garcia HH, Lescano AG, Lanchote V, Pretell EJ, Gonzales I, Bustos J, et al. Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis. Br J Clin Pharmacol. 2011;72:77-84.
37. Agapejev S, Da Silva MD, Ueda AK. Severe forms of neurocysticercosis: treatment with albendazole. Arq Neuropsiquiatr. 1996;54:82-93.
38. Gongora-Rivera F, Soto-Hernandez JL, Gonzalez Esquivel D, Cook HJ, Marquez-Caraveo C, Hernandez Davila R, et al. Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology. 2006;66:436-8.
39. Gonzalez AE, Bustos JA, Jimenez JA, Rodriguez ML, Ramirez MG, Gilman RH, et al. Efficacy of diverse antiparasitic treatments for cysticercosis in the pig model. Am J Trop Med Hyg. 2012;87:292-6.
40. Diazgranados-Sanchez JA, Barrios-Arrazola G, Costa JL, Burbano-Pabon J, Pinzon-Bedoya J. [Ivermectin as a therapeu- tic alternative in neurocysticercosis that is resistant to conven- tional pharmacological treatment]. Rev Neurol. 2008;46:671-4.
41. Sacerdote AS, Mejia JO, Bahtiyar G, Salamon O. Effect of raloxifene in human neurocysticercosis. BMJ Case Rep. 2012;2012:pii: bcr0620114417.
42. Sheth TN, Lee C, Kucharczyk W, Keystone J. Reactivation of neurocysticercosis: case report. Am J Trop Med Hyg. 1999;60:664-7.
43. Nash TE, Patronas NJ. Edema associated with calcified lesions in neurocysticercosis. Neurology. 1999;53:777-81.
44. Nash TE, Pretell J, Garcia HH. Calcified cysticerci provoke perilesional edema and seizures. Clin Infect Dis. 2001;33:1649-53.
45. Nash TE, Pretell EJ, Lescano AG, Bustos JA, Gilman RH, Gonzalez AE, et al. Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol. 2008;7:1099-105.
46. Zhang Y, Wang C, Liu P, Gao X. Clinical application of neuroendoscopic techniques. Stereotact Funct Neurosurg. 2000;75:133-41.
47. Proano JV, Torres-Corzo J, Rodriguez-Della Vecchia R, Guizar-Sahagun G, Rangel-Castilla L. Intraventricular and subarachnoid basal cisterns neurocysticercosis: a comparative study between traditional treatment versus neuroendoscopic surgery. Childs Nerv Syst. 2009;25:1467-75.